查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984880

全球流感疫苗市场：依疫苗类型、生产流程、给药途径、年龄层、通路及地区划分－市场规模、产业动态、机会分析及预测（2026-2035 年）

Global Influenza Vaccine Market: By Type, By Process, Route of Administration, Age Group, Distribution Channel, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 312 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球流感疫苗市场正经历快速转型和显着成长。预计到 2025 年，市场规模将达到约 107.7 亿美元，到 2035 年将达到 307.7 亿美元。这一增长意味着在 2026 年至 2035 年的预测期内，复合年增长率 (CAGR) 将达到 11.07%。推动市场扩张的主要因素包括全球季节性流感发病率的上升、人口老化等人口结构变化，以及各国政府为提高疫苗接种率和加强公共卫生防范所做的努力。

季节性流感爆发的频率和严重程度不断增加是市场成长的主要驱动因素之一。流感仍然是一项重大的公共卫生挑战，每年感染数百万人，导致高发病率和高死亡率，尤其是在老年人和慢性病患者等弱势群体中。这项持续存在的威胁凸显了采取有效预防措施的迫切性，并推动了对流感疫苗的稳定需求。

主要市场趋势

流感疫苗市场的特点是主要参与者之间的激烈竞争，每家公司都试图透过强大的研发活动、扩大产品组合和建立策略联盟来巩固其市场地位。领先企业认识到创新和多元化对于满足不断变化的市场需求和应对流感病毒株变异的挑战至关重要。 赛诺菲在这个竞争激烈的市场中脱颖而出，成为主导力量，并透过将其疫苗产品组合转向高价值产品来积极捍卫其市场领导地位。这项策略措施包括专注于高价值疫苗，例如高剂量製剂和佐剂製剂，尤其针对老年人等弱势族群。 CSL正透过确立自身作为 "非鸡蛋来源" 流感疫苗领先​​供应商的地位，开闢出一个独特的细分市场。 CSL强调基于细胞培养的疫苗生产，为担心鸡蛋过敏或受鸡蛋适应性病毒突变限制的医护人员和患者提供了一种极具吸引力的传统鸡蛋来源疫苗替代方案。

葛兰素史克（GSK）则采取了不同的策略，将重点转向 "含佐剂疫苗" 策略，透过添加免疫增强物质来增强免疫反应。该策略针对对标准疫苗反应较弱的人群，例如老年人，旨在提高这些人群的疫苗整体有效性。

主要成长驱动因素

季节性流感发生率的上升是全球流感疫苗市场成长的关键驱动因素。每年，流感病毒都会导致广泛的感染，造成频繁且往往难以预测的疫情爆发，且疫情在不同地区的严重程度各不相同。这些季节性疫情对医疗系统造成沉重负担，导致住院和就诊人数增加，在严重病例中，死亡率也更高。疫情的反覆出现使得持续有效的预防措施变得尤为迫切，其中最重要的就是每年接种流感疫苗。

新机会与趋势

流感疫苗市场正经历重大变革，从传统的鸡蛋培养法转向细胞培养和重组疫苗生产等更新、更先进的技术。这一转变是一个充满希望的趋势，有望透过提高生产效率和疫苗效力来推动市场成长。虽然传统的鸡蛋培养法可靠且经济高效，但它也存在一些局限性，例如生产週期长以及病毒适应性问题，这些问题可能会降低疫苗效力。相较之下，细胞培养和重组技术提供了创新的解决方案，可以应对许多此类挑战，开启流感疫苗研发的新时代。

优化障碍

由于严格的监管要求和疫苗研发的高昂成本，流感疫苗市场的成长面临巨大的挑战。其中最大的障碍之一是漫长的研发週期。通常，从初步研究到获得市场批准需要 10 到 15 年的时间。如此漫长的过程反映了疫苗研发的复杂性，其中包括多阶段临床试验、严格的安全性和有效性测试以及全面的生产验证。这种延误不仅减缓了创新疫苗的上市速度，也增加了製造商的财务风险，因为他们必须投入大量资源多年才能获得投资回报。

目录

第一章：研究架构

  • 研究目标
  • 产品概述
  • 市场区隔

第二章：研究方法

  • 质性研究
    • 一手和二手资料
  • 量化研究
    • 一手和二手资料
  • 主要调查受访者分布：依地区划分
  • 本研究的假设
  • 市场规模估算
  • 数据三角测量

第三章：摘要整理：全球流感疫苗市场

第四章：全球流感疫苗市场概述

  • 产业价值链分析
    • 原料供应商
    • 製造商
    • 经销商
    • 终端用户
  • 行业展望
    • 65岁以上族群季节性流感呼吸道死亡率
    • 受影响最严重国家的国家流感中心
  • PESTLE分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场动态与趋势
    • 成长驱动因素
    • 挑战
    • 关键因素趋势
  • 市场成长与展望
    • 市场收入估计与预测（2020-2035 年）
    • 市场销售估算与预测（百万剂）（2020-2035 年）
    • 价格趋势分析
  • 竞争格局概述
    • 市场集中度
    • 公司占有率分析（价值，%），2025 年
    • 竞争格局图
  • 实务见解（分析师建议）

第五章 全球流感疫苗市场分析：依疫苗类型划分

  • 主要见解
  • 市场规模与预测：2020-2035 年（百万美元，百万剂）
    • 灭活​​疫苗流感疫苗 (IIV)
    • 减毒活流感疫苗 (LAIV)

第六章 全球流感疫苗市场分析：依生产流程划分

  • 主要见解
  • 市场规模与预测：2020–2035 年（百万美元，百万剂）
    • 鸡蛋来源
    • 细胞培养
    • 重组

第七章 全球流感疫苗市场分析：依给药途径划分

  • 主要见解
  • 市场规模与预测：2020–2035 年（百万美元，百万剂）剂量）
    • 注射剂
    • 鼻腔喷剂

第八章 全球流感疫苗市场分析：依年龄组别划分

  • 主要见解
  • 市场规模与预测：2020–2035 年（百万美元，百万剂）
    • 儿童
    • 成人

第九章 全球流感疫苗市场分析：依通路划分

  • 主要见解
  • 市场规模与预测：2020–2035 年（百万美元，百万剂）
    • 医院和药房
    • 政府供应商
    • 其他

第十章 全球流感疫苗市场分析：依地区划分

  • 主要见解
  • 市场规模与预测：2020–2035 年（百万美元，百万剂）
    • 北美
    • 欧洲
    • 亚太地区
    • 中东和非洲
    • 南美

第 11 章 北美流感疫苗市场分析

第 12 章 欧洲流感疫苗市场分析

第 13 章 亚太地区流感疫苗市场分析

第 14 章 中东与非洲流感疫苗市场分析

第 15 章 南美洲流感疫苗市场分析

第16章 企业简介

  • Abbott Laboratories
  • AstraZeneca
  • Emergent BioSolutions Inc
  • Emergex Vaccines Holding Limited
  • GSK plc
  • Merck &Co., Inc.
  • OSIVAX
  • Pfizer Inc.
  • Sanofi SA
  • CSL Limited
  • Sinovac Biotech Ltd.
  • SK bioscience Co., Ltd.
  • Viatris Inc.
  • Other Prominent Players

第17章 附录

简介目录
Product Code: AA0124744

The global influenza vaccine market is experiencing a period of rapid transformation and substantial growth. Valued at approximately US$ 10.77 billion in 2025, the market is projected to expand significantly, reaching an estimated valuation of US$ 30.77 billion by 2035. This growth corresponds to a robust compound annual growth rate (CAGR) of 11.07% over the forecast period from 2026 to 2035. Several key factors are driving this expansion, including the increasing incidence of seasonal influenza cases worldwide, demographic shifts characterized by a growing aging population, and enhanced government initiatives aimed at bolstering vaccination coverage and public health preparedness.

One of the primary contributors to the market's growth is the rising frequency and severity of seasonal flu outbreaks. Influenza continues to pose a major public health challenge, with millions affected annually, leading to substantial morbidity and mortality, especially among vulnerable groups such as the elderly and individuals with chronic health conditions. This ongoing threat underscores the critical need for effective preventive measures, fueling consistent demand for influenza vaccines.

Noteworthy Market Developments

The influenza vaccine market is characterized by intense competition among major players, each striving to strengthen its position through robust research and development efforts, portfolio expansion, and strategic collaborations. Leading companies recognize the importance of innovation and diversification to meet evolving market demands and to address the challenges posed by changing influenza virus strains.

Sanofi stands out as a dominant force in this competitive landscape, aggressively defending its market leadership by transitioning its vaccine portfolio toward premium products. This strategic move involves focusing on high-value vaccines such as high-dose and adjuvanted formulations, which cater especially to vulnerable populations like seniors. CSL has carved out a distinctive niche by positioning itself as the leading provider of "Non-Egg" influenza vaccines. By emphasizing cell-based vaccine production, CSL offers an alternative to traditional egg-based vaccines that appeals to healthcare providers and patients concerned about egg allergies or the limitations associated with egg-adapted viral mutations.

GlaxoSmithKline (GSK) has adopted a different approach by pivoting toward an adjuvanted vaccine strategy, which involves enhancing immune responses through the inclusion of immune-boosting substances. This strategy targets populations that may have weaker responses to standard vaccines, such as older adults, aiming to improve overall vaccine efficacy in these groups.

Core Growth Drivers

The rising incidence of seasonal influenza is a significant factor fueling the growth of the influenza vaccine market worldwide. Each year, influenza viruses cause widespread illness, leading to frequent and often unpredictable outbreaks that vary in severity across different regions. These seasonal epidemics place a considerable burden on healthcare systems, resulting in increased hospitalizations, medical consultations, and, in severe cases, mortality. The recurring nature of these outbreaks creates a continuous and urgent need for effective preventative measures, chief among them being annual influenza vaccinations.

Emerging Opportunity Trends

The influenza vaccine market is undergoing a significant transformation as it shifts from traditional egg-based manufacturing methods to newer, more advanced technologies such as cell-based and recombinant vaccine production. This transition represents a promising trend that is expected to drive market growth by enhancing both production efficiency and vaccine effectiveness. Traditional egg-based methods, while reliable and cost-effective, present certain limitations, including longer production timelines and potential issues with virus adaptation that can reduce vaccine efficacy. In contrast, cell-based and recombinant technologies offer innovative solutions that address many of these challenges, heralding a new era in influenza vaccine development.

Barriers to Optimization

The growth of the influenza vaccine market faces significant challenges due to stringent regulatory requirements and the high costs associated with vaccine development. One of the most critical barriers is the lengthy development timeline, which typically spans 10 to 15 years from initial research to market approval. This extended period reflects the complexity of vaccine development, which involves multiple phases of clinical trials, rigorous safety and efficacy testing, and comprehensive manufacturing validation. Such protracted timelines not only delay the introduction of innovative vaccines but also increase the financial risks for manufacturers, who must invest substantial resources over many years before seeing any return.

Detailed Market Segmentation

By Vaccine Type, the Inactivated Influenza Vaccine (IIV) segment overwhelmingly dominates the influenza vaccine market, commanding an impressive 89.60% share. This substantial market presence is largely rooted in the vaccine's well-established safety profile and its widespread acceptance as the standard of care across nearly all demographic groups. IIVs have long been trusted by healthcare professionals and patients alike, making them the go-to choice for influenza immunization worldwide. Their broad applicability, from children to elderly adults, has solidified their position as the cornerstone of influenza prevention strategies.

By Process, the egg-based process continues to hold a significant position in the influenza vaccine market, capturing a substantial 46.28% share according to the latest data. This manufacturing method remains the cornerstone of global vaccine production, primarily due to its cost-effectiveness and scalability. Despite advances in alternative production technologies, egg-based vaccine manufacturing has proven to be a reliable and practical solution, especially when it comes to meeting the immense annual global demand for influenza vaccines.

By Route of Administration, the injectable route remains the predominant method of administration in the influenza vaccine market, commanding a substantial 71.03% share. This dominance is largely attributed to its compatibility with the most widely used vaccine types-primarily the inactivated influenza vaccines (IIV) and recombinant influenza vaccines (RIV). These vaccine formulations are designed for intramuscular or subcutaneous injection, which remains the standard and most trusted approach for delivering influenza immunizations across diverse patient populations.

By Age Group, adults represent the largest consumer group within the influenza vaccine market, commanding an impressive 78.25% share of the overall market. This dominance is a critical factor in understanding the profitability dynamics within the industry. The adult demographic's substantial market share highlights not only the volume of vaccines administered but also the economic significance of this segment for manufacturers and healthcare providers. Unlike other groups, adults-particularly older adults-are the primary drivers of revenue growth and market value, making them the focal point for strategic targeting and product development.

Segment Breakdown

By Type

  • Inactivated influenza vaccine (IIV)
  • Quadrivalent
  • Trivalent
  • Live-attenuated influenza vaccine (LAIV)

By Process

  • Egg Based
  • Cell Culture-Based
  • Recombinant

By Route of Administration

  • Injectable
  • Intra-nasal

By Age Group

  • Pediatric
  • Adult

By Distribution Channel

  • Hospitals & Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
  • South America

Geography Breakdown

  • North America stands out as the primary value hub in the global influenza vaccine market, with the United States and Canada representing the highest value region worldwide despite not having the largest population. This distinction is largely due to the unique characteristics of the US healthcare system, particularly its "Open Market" model. Unlike many countries where vaccine pricing is tightly regulated or capped by single-payer government tenders, the US allows for more flexible pricing structures. This open market environment enables manufacturers to introduce and widely distribute premium influenza vaccines.
  • Another critical factor underpinning North America's leadership in this sector is the highly optimized supply chain that supports vaccine distribution. The region benefits from a robust and efficient retail pharmacy infrastructure, with major chains such as CVS and Walgreens playing pivotal roles as primary points of care for influenza vaccination. These pharmacies provide convenient, accessible locations for patients to receive their vaccines without the need for a doctor's appointment, facilitating higher vaccination rates and improving public health outcomes.

Leading Market Participants

  • Abbott Laboratories
  • AstraZeneca
  • Emergent BioSolutions Inc
  • Emergex Vaccines Holding Limited
  • GSK plc
  • Merck & Co., Inc.
  • OSIVAX
  • Pfizer Inc.
  • Sanofi SA
  • CSL Limited
  • Sinovac Biotech Ltd.
  • SK Bioscience Co., Ltd.
  • Viatris Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Influenza Vaccine Market

Chapter 4. Global Influenza Vaccine Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Respiratory mortality rate from seasonal influenza in the over-65's
    • 4.2.2. National Influenza Centers in Most Affected Countries
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Challenges
    • 4.5.3. Key Trends
  • 4.6. Market Growth and Outlook
    • 4.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 4.6.2. Market Volume Estimates and Forecast (Mn Doses), 2020-2035
    • 4.6.3. Price Trend Analysis
  • 4.7. Competition Dashboard
    • 4.7.1. Market Concentration Rate
    • 4.7.2. Company Market Share Analysis (Value %), 2025
    • 4.7.3. Competitor Mapping
  • 4.8. Actionable Insights (Analyst's Recommendations)

Chapter 5. Global Influenza Vaccine Market Analysis, By Vaccine Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 5.2.1. Inactivated influenza vaccine (IIV)
      • 5.2.1.1. Quadrivalent
      • 5.2.1.2. Trivalent
    • 5.2.2. Live-attenuated influenza vaccine (LAIV)

Chapter 6. Global Influenza Vaccine Market Analysis, By Process

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 6.2.1. Egg Based
    • 6.2.2. Cell Culture-Based
    • 6.2.3. Recombinant

Chapter 7. Global Influenza Vaccine Market Analysis, By Route of Administration

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 7.2.1. Injectable
    • 7.2.2. Intra-Nasal

Chapter 8. Global Influenza Vaccine Market Analysis, By Age Group

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 8.2.1. Paediatric
    • 8.2.2. Adult

Chapter 9. Global Influenza Vaccine Market Analysis, By Distribution Channel

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 9.2.1. Hospitals & Pharmacies
    • 9.2.2. Government Suppliers
    • 9.2.3. Others

Chapter 10. Global Influenza Vaccine Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Influenza Vaccine Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 11.2.1. By Vaccine Type
    • 11.2.2. By Process
    • 11.2.3. By Route of Administration
    • 11.2.4. By Age Group
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country

Chapter 12. Europe Influenza Vaccine Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 12.2.1. By Vaccine Type
    • 12.2.2. By Process
    • 12.2.3. By Route of Administration
    • 12.2.4. By Age Group
    • 12.2.5. By Distribution Channel
    • 12.2.6. By Country

Chapter 13. Asia Pacific Influenza Vaccine Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 13.2.1. By Vaccine Type
    • 13.2.2. By Process
    • 13.2.3. By Route of Administration
    • 13.2.4. By Age Group
    • 13.2.5. By Distribution Channel
    • 13.2.6. By Country

Chapter 14. Middle East & Africa Influenza Vaccine Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 14.2.1. By Vaccine Type
    • 14.2.2. By Process
    • 14.2.3. By Route of Administration
    • 14.2.4. By Age Group
    • 14.2.5. By Distribution Channel
    • 14.2.6. By Country

Chapter 15. South America Influenza Vaccine Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 15.2.1. By Vaccine Type
    • 15.2.2. By Process
    • 15.2.3. By Route of Administration
    • 15.2.4. By Age Group
    • 15.2.5. By Distribution Channel
    • 15.2.6. By Country

Chapter 16. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 16.1. Abbott Laboratories
  • 16.2. AstraZeneca
  • 16.3. Emergent BioSolutions Inc
  • 16.4. Emergex Vaccines Holding Limited
  • 16.5. GSK plc
  • 16.6. Merck & Co., Inc.
  • 16.7. OSIVAX
  • 16.8. Pfizer Inc.
  • 16.9. Sanofi SA
  • 16.10. CSL Limited
  • 16.11. Sinovac Biotech Ltd.
  • 16.12. SK bioscience Co., Ltd.
  • 16.13. Viatris Inc.
  • 16.14. Other Prominent Players

Chapter 17. Annexure

  • 17.1. List of Secondary Sources
  • 17.2. Key Country Markets - Macro Economic Outlook/ Indicators